• 1
    National Institute of Drug Abuse. Research Report Series: Methamphetamine Abuse and Addiction. Bethesda, MD: National Institutes of Health; 2002. NIH publication No. 02–4210.
  • 2
    U.S. Drug Enforcement Administration. Methamphetamine. Available at: Acce- ssed February 16, 2007.
  • 3
    Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006; 81: 7784.
  • 4
    Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings, September 2005.
  • 5
    Albertson T, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med. 1999; 170: 214219.
  • 6
    Beebe D, Walley E. Smokable methamphetamine (“Ice”): an old drug in a different form. Am Family Physician. 1995; 51: 449453.
  • 7
    Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA. 1991; 265: 11521154.
  • 8
    Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol. 2003; 41: 981986.
  • 9
    Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007; 120: 165171.
  • 10
    Members of the Chamber Quantification Writing Group. Recommendations for Chamber Quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 14401463.
  • 11
    Rossi A, Cicoria M, Zanolla L, et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2002; 40: 1425.
  • 12
    Dini FL, Cortigiani L, Baldini U, et al. Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Am J Cardiol. 2002; 89: 518523.
  • 13
    Sun JP, James KB, Yang XS, et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated vs nondilated right ventricular cavities. Am J Cardiol. 1997; 80: 15831587.
  • 14
    Jacobs LJ. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol. 1989; 12: 725727.
  • 15
    Islam MN, Kuroki H, Hongcheng B, et al. Cardiac lesions and their reversibility after long term administration of methamphetamine. Foren Sci Int. 1995; 75: 2943.
  • 16
    He SY, Matoba R, Fujitani N, Sodesaki K, Onishi S. Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol. 1996; 17: 155162.
  • 17
    Henning RJ, Cuevas J. Cocaine activates calcium/calmodulin kinase II and causes cardiomyocyte hypertrophy. J Cardiovasc Pharmacol. 2006; 48: 802813.
  • 18
    Logan BK, Fligner CL, Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci. 1998; 43: 2834.
  • 19
    Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999; 44: 359368.
  • 20
    Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986; 57: 450458.